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Abstract 
The candidate tumor suppressor gene 
ZMYND10/BLU, is located on the minimal deleted 
fragment of 110 kb in chromosomal region 3p21.3. 
It was initially identified by PCR in search of the b-
catenin homolog in lung cancer. BLU codes for a 
protein with 440 amino acid residues, which 
contains a zinc finger myelogenous nervy domain 
(zMYND) motif on its carboxyl terminus. The 
characteristic domain defines a ZMYNND protein 
family, some of its member have been found in the 
frequently affected region translocated during acute 
leukemias, and were described to be transcriptional 
repressors. BLU/ZMYND10 is inactivated in a 
variety of human tumors due to genetic or 
epigenetic mechanisms, but the function is largely 
unknown. It has been reported that similar with 
certain tumor suppressors, it donwregulates 
JNK/MAPK signaling to exert inhibition on growth 
and proliferation. ZMYND10 is implicated in the 
respiratory ciliary dyskinesia. 
Identity 
Other names: BLU, CILD22, FLU 
HGNC (Hugo): ZMYND10 
Location: 3p21.31 
Local order 




NM_015896, 4.7 kb. 
Description 
The genomic size of the gene is about 4.5 kb. 
The gene of 4.5-4.7 kb contains 12 (lung version, termed as canonic) or 11 (testis version) exons coding for a 2-kb, alternatively 
spliced mRNA, well expressed in lung and testis but not expressed in all other tested human tissues. 












The testis isoform contains 11 exons because of a 
complex selection of an alternative acceptor site. 
Pseudogene 
No known pseudogenes. 
Protein 
Note 
NP_056980; ZMYND10 (zinc finger, myeloid, 
nervy and DEAF-1 (MYND)-type containing 10). 
Description 
The BLU protein is likely a soluble cytoplasmic 
protein and shares 30-32% identity over a stretch of 
100-112 amino acids (residues 334-437 or 318-430) 
with proteins of the MTG/ETO family of 
transcription factors and the suppressins.  
The most notable feature of the protein is a C-
terminal MYND domain, spanning residues 394-
430.  
The MYND domain constitutes a protein-protein 
interaction surface that appears to allow these 
proteins to act as transcriptional co-repressors by 
association with a variety of chromatin remodelling 
and transcription. 
Expression 
Low level expression in most human tissues. 
Localisation 
A majority of its coding product is located in 
cytoplasma. 
Function 
The function of BLU/ZMYND10 is unknown. As a 
MYND-containing protein BLU/ZMYND10 is 
most likely to be involved in important 
transcriptional regulation pathways.  
It has been reported that BLU regulate cell cycle 
progression through inhibition JNK signaling. 
Homology 
Shares 30-32% identity over a stretch of 100-112 
amino acids (residues 334-437 or 318-430) with 
proteins of the MTG/ETO family of transcription 
factors and the suppressins. 
Mutations 
Note 
The lung isoform is regarded as canonic isoform. 
The testis-specific protein isoform contains a 
different amino acid sequence between residues 199 
and 234 as compared with the canonic lung-specific 
isoform.  
Mutation of BLU/ZMYND10 within a given 
isoform is a rare event in lung cancer and other 
cancers since missense changes were detected in 
only 3/61 lung tumour-cell lines. The eight-gene set 
in the 120-kb region show that the mutation rate 
was in the range of 5%. Missense mutations were 
discovered in a sample of 61 lung cancer cell lines. 
It has been shown that, however, mutated 
ZMYND10 protein carrying substitution of some 
amino acid residues binds LRRC6 and contributes 
to pathogenesis of primary ciliary dyskinesia (PCD, 
or CILD22). 
Somatic 
Mutation carried by testis isoform 200-234: 
SLSLSTLSRMLSTHNLPCLLVELLEHSPWSRR
EGG→RQWSVSQPPQLAHLKRIQRLHPVCWF
LSPG; results in the loss of one of three PKC 
phosphorylation sites (residues 229-231). The 
substitutions documented in PCD include: 
ZMYND10, VAL16GLY, SER29PRO, 
LEU39PRO, LEU266PRO, ARG369TRP, 
Tyr379CYS, and ASP198GLN, ARG407GLU in 




The gene codes for the putative tumor suppressor 
BLU is primarily expressed in the lung and testis, 
as tissue-specific isoforms, but the level is low in 
other tissues. The expression is varied in lung 
cancer cells, but a non-small lung cancer line, A549 
has high level of BLU. A majority of 
nasopharyngeal carcinoma-derived cell lines, 
however, has downregulated expression of BLU. 
Mutation of the gene is relatively rare.  
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Hypermethylation on BLU promoter has been 
detected ranging from 19% of primary non-small 
cell lung cancer to 66-74% of nasopharyngeal 
carcinoma (NPC). 
Disease 
Mutated BLU/ZMYND10 protein with several 
amino acid residues substitution has been shown to 
associate with LRRC6, and plays a role in the 
pathogenesis of primary ciliary dyskinesia. 
Hypermethylation and downregulation has been 
described as a frequent event in primary tumours 
such as glioma (80%), cervical squamous cell 
carcinomas (77%), NPC (66%), neuroblastoma (41-
70%) and NSCLC (19-43%) with lower frequencies 
observed in gallbladder carcinomas (26%), 
ependymomas (13.6%) and SCLC (14%). It has 
been noted that in some tumors like glioma, 
methylation of BLU is an early detectable event; it 
was identified in stage II glioma and stage I/II 
cervical squamous cell carcinomas. 
Cytogenetics 
Unlike t(8;21) translocation frequently seen in acute 
myelogenous leukemia, involving ZMYND motif 
containing MTG8, no cytogenetic anomaly 
affecting BLU has been observed in malignancies. 
Hybrid/Mutated gene 




BLU is primarily expressed in lung and testis, with 
different isoforms. The mutation is rare. The 
expression is absent in a number of lung cancer cell 
lines, and in 19-43% of non-small lung cancer 
(NSLC) cases, BLU is silenced due to promoter 
hypermethylation (Agathanggelou et al., 2003; 
Marsit et al., 2005). The incidence is higher in 
adenocarcinoma (AC) than in squamous cell 
carcinoma (SCC). Frequent methylation for BLU 
and RASSF1 has been observed but there is no 
significant association. In lung cancer patients, 
homozygous deletion of 3p21 region has been 
association with early age of cigarette smoking 
initiation. 
Nasopharyngeal carcinoma (NPC) 
Note 
Downregulation of BLU expression was well 
correlated with the promoter hypermethylation in 
tumor specimens and cultured cell lines. 
Methylation on BLU promoter was identified in up 
to 66% of the tumors, and 6 out 7 passaged cell 
lines. BLU was observed to inhibit JNK signaling 
pathway, and cyclin D1 (CCND1) gene promoter 
activity, arrest cell cycle at G1 phase, and block in 
vitro and in vivo NPC cell growth. 
Glioma 
Note 
BLU/ZMYND10 hypermethylation and 
downregulation has been described as a frequent 
event in up to 80% primary tumours of glioma. 
BLU/ZMYND10 methylation is an early event 
detectable in stage II glioma (Hesson et al., 2004). 
In glioma tumours methylation of BLU/ZMYND10 
and/or RASSF1A, located adjacent to 
BLU/ZMYND10, was detected in more than 95% 
(52/54) primary tumours. 
Neuroblastoma 
Note 
Methylation leading to downregulation of BLU has 
been described in up to 70% neuroblastoma (41-
70%) (Abe et al., 2005). It was shown that 
methylation of promoter CGIs of RASSF1A (3p21) 
and BLU (3p21) was far more frequently observed 




In esophageal squamous cell carcinoma (ESCC), 
BLU expression was downregulated in three out of 
four Asian esophageal carcinoma cell lines, and 4 
out of 8 pairs of tumor and normal tissues. 
Methylation specific-PCR revealed the down-
regulation of BLU by epigenetic inactivation. 
However, exogenous expression of BLU did not 
functionally suppress tumorigenicity in nude mice. 
These results suggest that over-expression of BLU 
alone is not sufficient to inhibit tumorigenicity. (Yi 
Lo et al., 2006). 
Ovarian carcinoma 
Note 
Epithelial ovarian carcinoma is usually present at 
the advanced stage, during which the patients 
generally have poor prognosis. Our study aimed to 
evaluate the correlation of gene methylation and the 
clinical outcome of patients with advanced-stage, 
high-grade ovarian serous carcinoma. The 
methylation status of eight candidate genes was 
first evaluated by methylation-specific PCR and 
capillary electrophoresis to select three potential 
genes including DAPK, CDH1, and BLU 
(ZMYND10) from the exercise group of 40 
patients. The methylation status of these three genes 
was further investigated in the validation group 
consisting of 136 patients. Patients with methylated 
BLU had significantly shorter progression-free 
survival (PFS; hazard ratio (HR) 1.48, 95% CI 
1.01-2.56, P=0.013) and overall survival (OS; HR 
1.83, 95% CI 1.07-3.11, P=0.027) in the 
multivariate analysis. Methylation of BLU was also 
an independent risk factor for 58 patients  
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undergoing optimal debulking surgery for PFS (HR 
2.37, 95% CI 1.03-5.42, P=0.043) and OS (HR 
3.96, 95% CI 1.45-10.81, P=0.007) in the 
multivariate analysis. A possible mechanism of 
BLU in chemoresistance was investigated in 
ovarian cancer cell lines by in vitro apoptotic 
assays. In vitro studies have shown that BLU could 
upregulate the expression of BAX and enhance the 
effect of paclitaxel-induced apoptosis in ovarian 
cancer cells. Our study suggested that methylation 
of BLU could be a potential prognostic biomarker 
for advanced ovarian serous carcinoma. 
Prognosis 
Its correlation with prognosis of serous ovarian 
carcinoma has been documented.  
The methylation status of eight candidate genes, 
including BLU was first evaluated by methylation-
specific PCR and capillary electrophoresis from 
tumor tissues of ovarian carcinoma in a group of 
patients. Patients with methylated BLU had 
significantly shorter progression-free survival and 
overall survival in the multivariate analysis (Chiang 
et al., 2013). 
Myelodysplastic syndrome (MDS) 
Note 
Hypermethylation in the promoter region and 
downregulation at mRNA and protein levels of 
BLU was detected in 34 of 79 (43%) MDS patient 
samples.  
There was a statistically significant difference in 
methylation frequency between different refractory 
anemia groups. The demethylating agent decitabine 
could partly reverse hypermethylation and restore 
the expression of the BLU gene. BLU promoter 
hypermethylation frequently occurs in higher risk 
MDS cases. BLU may play a role in the 
development and etiology of MDS. 
Primary ciliary dyskinesia (PCD) 
Note 
ZMYND10 bound to LRRC6 in HEK293T and in 
human tracheal epithelial cells. These two proteins 
localized to both the basal body and the striated 
rootlet in Xenopus ciliated epithelial cells.  
The C-terminal MYND domain of ZMYND10 was 
insufficient for interaction with the CS domain of 
LRRC6; but a C-terminal fragment expanding 366-
440 amino acids extending beyond the MYND 
domain was necessary for interaction (see the 
scheme of protein diagram).  
Similar studies using progressive truncating 
constructs of LRRC6 confirmed that the C-terminal 
CS domain of LRRC6 is sufficient for the binding 
with ZMYND10.  
The protein-protein interaction is abrogated by 
truncating mutations in either gene in patients with 
CILD. 
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